To evaluate the efficacy and safety of 1470-nm Diode Laser Enucleation of the Prostate (DiLEP) in patients with benign prostatic hyperplasia (BPH) continuously receiving oral anticoagulants or antiplatelet drugs.
From January 2016 to June 2017, 144 patients were submitted to 1470-nm DiLEP, including forty-nine (34.0%) continuously administered anticoagulants or antiplatelet drugs per os due to cardiac and/or cerebrovascular diseases (Group A), while ninety-five (66.0%) were not (Group B). Evaluation was performed preoperatively, and at postoperative 3, 6, and 12 months, respectively. Patient baseline features, operative data, perioperative complications and postsurgical outcomes were assessed.
Both groups had comparable preoperative parameters, except age (77.3±7.5 vs 73.2±8.8 years, P=0.007). Meanwhile, surgical time, sodium decrease, catheterization duration and hospital stay markedly differed between the two groups. In comparison with group B, group A patients had statistically higher blood loss (14.9±7.3 g/L vs 10.2±7.0 g/L, P<0.001) and increased bladder irrigation time (21.1±10.9h vs 16.1±9.0h, P=0.004). One case required blood transfusion in group A, because of moderate anemia preoperatively. Both groups showed similar blood transfusion and complication rates. IPSS, QoL score, Qmax and PVR were markedly improved in both groups at 3, 6, and 12-months follow-up postoperatively compared with baseline values. However, no statistically significant differences were observed between the two groups in various assessment parameters at follow-up (P>0.05).
These findings demonstrated that 1470-nm DiLEP is efficient and safe in BPH cases receiving continuous oral anticoagulant or antiplatelet drugs. Anticoagulation therapy did not significantly influence the results and complication rates.

Copyright © 2020. Published by Elsevier Inc.